Lupin and Mylan Launch Nepexto (biosimilar- etanercept) in Germany

Share this

Lupin and Mylan Launch Nepexto (biosimilar- etanercept) in Germany


  • The companies launch Nepexto- a biosimilar referencing Amgen's Enbrel- and is indicated for the mod. to sev. RA- JIA from the age of 2yrs.- active and progressive PsA- severe axSpA- mod. to sev. PsO and chronic severe PsO in children and adolescents from the age of 6yrs.
  • Nepexto is available as a solution for injection in a pre-filled pen and prefilled syringe and has shown equivalent efficacy and safety to Enbrel
  • The EC has approved MAA to Nepexto on Jun 04- 2020- following CHMP’s positive opinion. The approval underlines the scientific success of Mylan’s biologics program and expands Mylan’s therapeutic portfolio for immune-mediated diseases including RA

­ Ref: Lupin | Image: mAbxience

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions